Effects of Liver Disease on Pharmacokinetics · Effects of Liver Disease on Pharmacokinetics Juan...
Transcript of Effects of Liver Disease on Pharmacokinetics · Effects of Liver Disease on Pharmacokinetics Juan...
![Page 1: Effects of Liver Disease on Pharmacokinetics · Effects of Liver Disease on Pharmacokinetics Juan J.L. Lertora, M.D., Ph.D. Director Clinical Pharmacology Program November 3, 2011](https://reader031.fdocuments.us/reader031/viewer/2022022710/5bf208bd09d3f2fb7d8c9242/html5/thumbnails/1.jpg)
Effects of Liver Disease on Pharmacokinetics Juan J.L. Lertora, M.D., Ph.D.
Director Clinical Pharmacology Program
November 3, 2011 National Institutes of Health
Clinical Center
![Page 2: Effects of Liver Disease on Pharmacokinetics · Effects of Liver Disease on Pharmacokinetics Juan J.L. Lertora, M.D., Ph.D. Director Clinical Pharmacology Program November 3, 2011](https://reader031.fdocuments.us/reader031/viewer/2022022710/5bf208bd09d3f2fb7d8c9242/html5/thumbnails/2.jpg)
2
GOALS of Liver Disease Effects Lecture -Estimation of Hepatic Clearance
- Effect of Liver Disease on Elimination:
- RESTRICTIVELY Eliminated Drugs
- NON-RESTRICTIVELY Eliminated Drugs
- Other Effects of Liver Disease:
- Renal Function
- Drug Distribution
- Drug Response
- Modification of Drug Therapy in Patients with Liver Disease
![Page 3: Effects of Liver Disease on Pharmacokinetics · Effects of Liver Disease on Pharmacokinetics Juan J.L. Lertora, M.D., Ph.D. Director Clinical Pharmacology Program November 3, 2011](https://reader031.fdocuments.us/reader031/viewer/2022022710/5bf208bd09d3f2fb7d8c9242/html5/thumbnails/3.jpg)
3
ADDITIVITY of Clearances
Equation showing that total elimination clearance equals the sum
of renal and nonrenal clearances
![Page 4: Effects of Liver Disease on Pharmacokinetics · Effects of Liver Disease on Pharmacokinetics Juan J.L. Lertora, M.D., Ph.D. Director Clinical Pharmacology Program November 3, 2011](https://reader031.fdocuments.us/reader031/viewer/2022022710/5bf208bd09d3f2fb7d8c9242/html5/thumbnails/4.jpg)
4
CALCULATION OF CLH
Equation showing that hepatic clearance is estimated as the total clearance minus the
renal clearance, assuming that it equals non-renal clearance.
![Page 5: Effects of Liver Disease on Pharmacokinetics · Effects of Liver Disease on Pharmacokinetics Juan J.L. Lertora, M.D., Ph.D. Director Clinical Pharmacology Program November 3, 2011](https://reader031.fdocuments.us/reader031/viewer/2022022710/5bf208bd09d3f2fb7d8c9242/html5/thumbnails/5.jpg)
5
FICK EQUATION
Defines clearance as liver blood flow times the extraction ratio A-V/A.
![Page 6: Effects of Liver Disease on Pharmacokinetics · Effects of Liver Disease on Pharmacokinetics Juan J.L. Lertora, M.D., Ph.D. Director Clinical Pharmacology Program November 3, 2011](https://reader031.fdocuments.us/reader031/viewer/2022022710/5bf208bd09d3f2fb7d8c9242/html5/thumbnails/6.jpg)
6
Derivation of Rowland Equation (I)
Diagram of hepatic capillary blood flow, fraction of unbound drug and intrinsic clearance
with the “well-stirred” model.
![Page 7: Effects of Liver Disease on Pharmacokinetics · Effects of Liver Disease on Pharmacokinetics Juan J.L. Lertora, M.D., Ph.D. Director Clinical Pharmacology Program November 3, 2011](https://reader031.fdocuments.us/reader031/viewer/2022022710/5bf208bd09d3f2fb7d8c9242/html5/thumbnails/7.jpg)
7
Derivation of Rowland Equation (II)
The same diagram now including volume and concentration terms and a mass balance
equation for hepatic drug clearance.
![Page 8: Effects of Liver Disease on Pharmacokinetics · Effects of Liver Disease on Pharmacokinetics Juan J.L. Lertora, M.D., Ph.D. Director Clinical Pharmacology Program November 3, 2011](https://reader031.fdocuments.us/reader031/viewer/2022022710/5bf208bd09d3f2fb7d8c9242/html5/thumbnails/8.jpg)
8
Derivation of Rowland Equation (III)
The same diagram with a derivation of an extraction ratio term that includes unbound
fraction, intrinsic clearance, and liver blood flow.
![Page 9: Effects of Liver Disease on Pharmacokinetics · Effects of Liver Disease on Pharmacokinetics Juan J.L. Lertora, M.D., Ph.D. Director Clinical Pharmacology Program November 3, 2011](https://reader031.fdocuments.us/reader031/viewer/2022022710/5bf208bd09d3f2fb7d8c9242/html5/thumbnails/9.jpg)
9
Rowland Equation WELL-STIRRED COMPARTMENT
Rowland Equation for hepatic clearance.
Two limiting cases:
Restrictively metabolized drugs (influenced by protein binding)
Non-restrictively metabolized drugs (blood flow-dependent)
![Page 10: Effects of Liver Disease on Pharmacokinetics · Effects of Liver Disease on Pharmacokinetics Juan J.L. Lertora, M.D., Ph.D. Director Clinical Pharmacology Program November 3, 2011](https://reader031.fdocuments.us/reader031/viewer/2022022710/5bf208bd09d3f2fb7d8c9242/html5/thumbnails/10.jpg)
10
RESTRICTIVELY AND NON-RESTRICTIVELY
ELIMINATED DRUGS
RESTRICTIVELY METABOLIZED DRUGS:
Phenytoin
Warfarin
Theophylline
NON-RESTRICTIVELY METABOLIZED DRUGS:
Lidocaine
Propranolol
Morphine
![Page 11: Effects of Liver Disease on Pharmacokinetics · Effects of Liver Disease on Pharmacokinetics Juan J.L. Lertora, M.D., Ph.D. Director Clinical Pharmacology Program November 3, 2011](https://reader031.fdocuments.us/reader031/viewer/2022022710/5bf208bd09d3f2fb7d8c9242/html5/thumbnails/11.jpg)
11
HEPATIC FIRST-PASS METABOLISM
Equation for the extraction ratio A-V/A.
Illustration of hepatic first-pass metabolism and the portal and systemic circulations.
![Page 12: Effects of Liver Disease on Pharmacokinetics · Effects of Liver Disease on Pharmacokinetics Juan J.L. Lertora, M.D., Ph.D. Director Clinical Pharmacology Program November 3, 2011](https://reader031.fdocuments.us/reader031/viewer/2022022710/5bf208bd09d3f2fb7d8c9242/html5/thumbnails/12.jpg)
12
NON-RESTRICTIVELY Eliminated Drugs
These drugs have extensive first-pass metabolism.
Equation showing that hepatic clearance is a function of liver blood flow.
![Page 13: Effects of Liver Disease on Pharmacokinetics · Effects of Liver Disease on Pharmacokinetics Juan J.L. Lertora, M.D., Ph.D. Director Clinical Pharmacology Program November 3, 2011](https://reader031.fdocuments.us/reader031/viewer/2022022710/5bf208bd09d3f2fb7d8c9242/html5/thumbnails/13.jpg)
13
ACUTE VIRAL HEPATITIS - Acute inflammatory condition
- Mild and transient changes related to extent of disease in most cases. Infrequently severe and fulminant
-May become chronic and severe
- Changes in drug disposition less than in chronic disease
- Hepatic elimination returns to normal as disease resolves
![Page 14: Effects of Liver Disease on Pharmacokinetics · Effects of Liver Disease on Pharmacokinetics Juan J.L. Lertora, M.D., Ph.D. Director Clinical Pharmacology Program November 3, 2011](https://reader031.fdocuments.us/reader031/viewer/2022022710/5bf208bd09d3f2fb7d8c9242/html5/thumbnails/14.jpg)
14
CHRONIC LIVER DISEASE - Usually related to chronic alcohol use or viral hepatitis - Irreversible hepatocyte damage
─ Decrease in SERUM ALBUMIN concentration
─ Decrease in INTRINSIC CLEARANCE of drugs
─ Intrahepatic and extrahepatic shunting of blood from
functioning hepatocytes
─ FIBROSIS disrupts normal hepatic architecture
─ NODULES of regenerated hepatocytes form
![Page 15: Effects of Liver Disease on Pharmacokinetics · Effects of Liver Disease on Pharmacokinetics Juan J.L. Lertora, M.D., Ph.D. Director Clinical Pharmacology Program November 3, 2011](https://reader031.fdocuments.us/reader031/viewer/2022022710/5bf208bd09d3f2fb7d8c9242/html5/thumbnails/15.jpg)
15
RESTRICTIVELY METABOLIZED DRUGS: EFFECTS OF
LIVER DISEASE Equation showing that hepatic clearance equals unbound fraction times the
intrinsic clearance.
Chart showing that hepatic clearance increases if albumin decreases, and decreases if
intrinsic clearance decreases.
![Page 16: Effects of Liver Disease on Pharmacokinetics · Effects of Liver Disease on Pharmacokinetics Juan J.L. Lertora, M.D., Ph.D. Director Clinical Pharmacology Program November 3, 2011](https://reader031.fdocuments.us/reader031/viewer/2022022710/5bf208bd09d3f2fb7d8c9242/html5/thumbnails/16.jpg)
16
RESTRICTIVELY METABOLIZED DRUGS:
EFFECT OF PROTEIN BINDING CHANGES
Equations showing that free drug concentration at steady-state is a function of dosing rate
and intrinsic hepatic clearance.
![Page 17: Effects of Liver Disease on Pharmacokinetics · Effects of Liver Disease on Pharmacokinetics Juan J.L. Lertora, M.D., Ph.D. Director Clinical Pharmacology Program November 3, 2011](https://reader031.fdocuments.us/reader031/viewer/2022022710/5bf208bd09d3f2fb7d8c9242/html5/thumbnails/17.jpg)
17
FREE and TOTAL PHENYTOIN Levels
(DOSE = 300 MG/DAY)
Chart showing that total Phenytoin concentration is lower than normal in functionally
anephric patients but free Phenytoin concentration is the same.
![Page 18: Effects of Liver Disease on Pharmacokinetics · Effects of Liver Disease on Pharmacokinetics Juan J.L. Lertora, M.D., Ph.D. Director Clinical Pharmacology Program November 3, 2011](https://reader031.fdocuments.us/reader031/viewer/2022022710/5bf208bd09d3f2fb7d8c9242/html5/thumbnails/18.jpg)
18
RESTRICTIVELY METABOLIZED DRUGS: EFFECT
OF PROTEIN BINDING CHANGES
Chart showing a protein binding interaction with Warfarin. There is a transient increase
in free Warfarin concentration and prothrombin time.
![Page 19: Effects of Liver Disease on Pharmacokinetics · Effects of Liver Disease on Pharmacokinetics Juan J.L. Lertora, M.D., Ph.D. Director Clinical Pharmacology Program November 3, 2011](https://reader031.fdocuments.us/reader031/viewer/2022022710/5bf208bd09d3f2fb7d8c9242/html5/thumbnails/19.jpg)
19
RESTRICTIVELY METABOLIZED DRUGS: EFFECTS OF LIVER DISEASE
Equation showing that hepatic clearance equals unbound fraction times the
intrinsic clearance.
Chart showing that hepatic clearance increases if albumin decreases, and decreases if
intrinsic clearance decreases.
![Page 20: Effects of Liver Disease on Pharmacokinetics · Effects of Liver Disease on Pharmacokinetics Juan J.L. Lertora, M.D., Ph.D. Director Clinical Pharmacology Program November 3, 2011](https://reader031.fdocuments.us/reader031/viewer/2022022710/5bf208bd09d3f2fb7d8c9242/html5/thumbnails/20.jpg)
20
ROLE OF CYP ENZYMES IN HEPATIC DRUG
METABOLISM
Pie chart showing relative hepatic content of CYP enzymes and pie chart showing % of
drugs metabolized by CYP enzymes.
![Page 21: Effects of Liver Disease on Pharmacokinetics · Effects of Liver Disease on Pharmacokinetics Juan J.L. Lertora, M.D., Ph.D. Director Clinical Pharmacology Program November 3, 2011](https://reader031.fdocuments.us/reader031/viewer/2022022710/5bf208bd09d3f2fb7d8c9242/html5/thumbnails/21.jpg)
21
RESTRICTIVELY METABOLIZED DRUGS: EFFECT
OF CIRRHOSIS ON Clint
Chart illustrating % of normal intrinsic clearance for normal, mild, moderate, and severe
cirrhosis, and the impact on glucuronidation and CYP2D6, CY3A4, CYP2C19, and
CYP1A2.
![Page 22: Effects of Liver Disease on Pharmacokinetics · Effects of Liver Disease on Pharmacokinetics Juan J.L. Lertora, M.D., Ph.D. Director Clinical Pharmacology Program November 3, 2011](https://reader031.fdocuments.us/reader031/viewer/2022022710/5bf208bd09d3f2fb7d8c9242/html5/thumbnails/22.jpg)
22
PUGH-CHILD CLASSIFICATION OF LIVER DISEASE SEVERITY
Chart showing assessment parameters and assigned scores in addition to classification of
clinical severity of mild, moderate and severe.
![Page 23: Effects of Liver Disease on Pharmacokinetics · Effects of Liver Disease on Pharmacokinetics Juan J.L. Lertora, M.D., Ph.D. Director Clinical Pharmacology Program November 3, 2011](https://reader031.fdocuments.us/reader031/viewer/2022022710/5bf208bd09d3f2fb7d8c9242/html5/thumbnails/23.jpg)
23
CORRELATION OF LAB TEST RESULTS WITH
IMPAIRED CYP ENZYME FUNCTION
The Central Problem:
There is no laboratory test of liver function that is as useful for guiding drug dose
adjustment in patients with liver disease as is the estimation of creatinine clearance in
patients with impaired renal function.
![Page 24: Effects of Liver Disease on Pharmacokinetics · Effects of Liver Disease on Pharmacokinetics Juan J.L. Lertora, M.D., Ph.D. Director Clinical Pharmacology Program November 3, 2011](https://reader031.fdocuments.us/reader031/viewer/2022022710/5bf208bd09d3f2fb7d8c9242/html5/thumbnails/24.jpg)
24
CORRELATION OF SPECIAL TESTS OF LIVER FUNCTION
WITH CHILD-PUGH SCORES*
Chart showing changes in indocyanine green and sorbitol clearances, and the galactose
elimination and the antipyrine breath tests.
* Data from Herold C, et al. Liver 2001;21:260-5.
![Page 25: Effects of Liver Disease on Pharmacokinetics · Effects of Liver Disease on Pharmacokinetics Juan J.L. Lertora, M.D., Ph.D. Director Clinical Pharmacology Program November 3, 2011](https://reader031.fdocuments.us/reader031/viewer/2022022710/5bf208bd09d3f2fb7d8c9242/html5/thumbnails/25.jpg)
25
“PITTSBURGH COCKTAIL” APPROACH
DRUG ENZYME
CAFFEINE CYP 1A2
CHLORZOXAZONE CYP 2E1
DAPSONE CYP 3A + NAT2
DEBRISOQUIN CYP 2D6
MEPHENYTOIN CYP 2C19
* From: Frye RF, et al. Clin Pharmacol Ther 1997;62:365-76
![Page 26: Effects of Liver Disease on Pharmacokinetics · Effects of Liver Disease on Pharmacokinetics Juan J.L. Lertora, M.D., Ph.D. Director Clinical Pharmacology Program November 3, 2011](https://reader031.fdocuments.us/reader031/viewer/2022022710/5bf208bd09d3f2fb7d8c9242/html5/thumbnails/26.jpg)
26
RESTRICTIVELY METABOLIZED DRUGS:
EFFECTS OF LIVER DISEASE
Equation showing that hepatic blood flow equals unbound fraction times the
intrinsic clearance.
Chart showing that hepatic clearance increases if albumin decreases, and decreases if
intrinsic clearance decreases.
Portosystemic shunting reduces total hepatic clearance and increases free drug
concentration.
![Page 27: Effects of Liver Disease on Pharmacokinetics · Effects of Liver Disease on Pharmacokinetics Juan J.L. Lertora, M.D., Ph.D. Director Clinical Pharmacology Program November 3, 2011](https://reader031.fdocuments.us/reader031/viewer/2022022710/5bf208bd09d3f2fb7d8c9242/html5/thumbnails/27.jpg)
27
EFFECTS OF HEPATIC SHUNTING ON ROWLAND EQUATION*
Modified Rowland Equation accounting for shunt blood flow.
* From: McLean A, et al. Clin Pharmacol Ther 1979;25:161-6.
![Page 28: Effects of Liver Disease on Pharmacokinetics · Effects of Liver Disease on Pharmacokinetics Juan J.L. Lertora, M.D., Ph.D. Director Clinical Pharmacology Program November 3, 2011](https://reader031.fdocuments.us/reader031/viewer/2022022710/5bf208bd09d3f2fb7d8c9242/html5/thumbnails/28.jpg)
28
RESTRICTIVELY METABOLIZED DRUGS: EFFECTS OF HEPATIC SHUNTING*
Chart showing liver disease severity, QT, QP, QP/QT, and Antipyrine CLH
*From: McLean A, et al. Clin Pharmacol Ther 1979;25:161-6.
![Page 29: Effects of Liver Disease on Pharmacokinetics · Effects of Liver Disease on Pharmacokinetics Juan J.L. Lertora, M.D., Ph.D. Director Clinical Pharmacology Program November 3, 2011](https://reader031.fdocuments.us/reader031/viewer/2022022710/5bf208bd09d3f2fb7d8c9242/html5/thumbnails/29.jpg)
29
NON-RESTRICTIVELY METABOLIZED DRUGS: EFFECTS OF LIVER DISEASE
Equation for hepatic clearance = blood flow showing that changes in protein binding and
intrinsic clearance have no impact on hepatic clearance for these drugs.
Chart
* However, note that free concentration is
![Page 30: Effects of Liver Disease on Pharmacokinetics · Effects of Liver Disease on Pharmacokinetics Juan J.L. Lertora, M.D., Ph.D. Director Clinical Pharmacology Program November 3, 2011](https://reader031.fdocuments.us/reader031/viewer/2022022710/5bf208bd09d3f2fb7d8c9242/html5/thumbnails/30.jpg)
30
NON-RESTRICTIVELY METABOLIZED DRUGS: EFFECTS OF LIVER DISEASE
Equation for CLH =Q
Equation for hepatic clearance = blood flow showing that changes in protein binding and
intrinsic clearance have no impact on hepatic clearance for these drugs.
HOWEVER, fuCLint MAY NO LONGER BE >> Q
![Page 31: Effects of Liver Disease on Pharmacokinetics · Effects of Liver Disease on Pharmacokinetics Juan J.L. Lertora, M.D., Ph.D. Director Clinical Pharmacology Program November 3, 2011](https://reader031.fdocuments.us/reader031/viewer/2022022710/5bf208bd09d3f2fb7d8c9242/html5/thumbnails/31.jpg)
31
NON-RESTRICTIVELY METABOLIZED DRUGS: EFFECTS OF LIVER DISEASE
Equation for CLH = Q
Equation for hepatic clearance = blood flow showing that changes in protein binding and
intrinsic clearance have no impact on hepatic clearance for these drugs.
Decreased hepatic perfusion results in increased oral bioavailability (F).
![Page 32: Effects of Liver Disease on Pharmacokinetics · Effects of Liver Disease on Pharmacokinetics Juan J.L. Lertora, M.D., Ph.D. Director Clinical Pharmacology Program November 3, 2011](https://reader031.fdocuments.us/reader031/viewer/2022022710/5bf208bd09d3f2fb7d8c9242/html5/thumbnails/32.jpg)
32
EFFECTS OF HEPATIC SHUNTING ON ROWLAND EQUATION*
Modified Rowland Equation
* From: McLean A, et al. Clin Pharmacol Ther 1979;25:161-6.
![Page 33: Effects of Liver Disease on Pharmacokinetics · Effects of Liver Disease on Pharmacokinetics Juan J.L. Lertora, M.D., Ph.D. Director Clinical Pharmacology Program November 3, 2011](https://reader031.fdocuments.us/reader031/viewer/2022022710/5bf208bd09d3f2fb7d8c9242/html5/thumbnails/33.jpg)
33
NON-RESTRICTIVELY METABOLIZED DRUGS: EFFECTS OF DECREASED
LIVER PERFUSION*
Chart showing liver disease Severity, QT, QP, QP/QT, and ICG CLH (clearance of
indocyanine green)
* From: McLean A, et al. Clin Pharmacol Ther 1979;25:161-6.
![Page 34: Effects of Liver Disease on Pharmacokinetics · Effects of Liver Disease on Pharmacokinetics Juan J.L. Lertora, M.D., Ph.D. Director Clinical Pharmacology Program November 3, 2011](https://reader031.fdocuments.us/reader031/viewer/2022022710/5bf208bd09d3f2fb7d8c9242/html5/thumbnails/34.jpg)
34
INFLUENCE OF PORTOSYSTEMIC SHUNTING
ON ORAL BIOAVAILABILITY (f)
RESTRICTIVELY Eliminated Drugs:
Little change
NON-RESTRICTIVELY Eliminated Drugs:
SHUNTING may markedly increase extent
of drug absorption (F)
![Page 35: Effects of Liver Disease on Pharmacokinetics · Effects of Liver Disease on Pharmacokinetics Juan J.L. Lertora, M.D., Ph.D. Director Clinical Pharmacology Program November 3, 2011](https://reader031.fdocuments.us/reader031/viewer/2022022710/5bf208bd09d3f2fb7d8c9242/html5/thumbnails/35.jpg)
35
CIRRHOSIS AFFECTS EXPOSURE TO SOME
NON-RESTRICTIVELY METABOLIZED DRUGS
Chart showing increased Absolute Bioavailability and relative exposure cirrhotics/control
of Meperidine, Pentazocine, and Propranolol.
* THIS ALSO INCORPORATES 55% INCREASE IN PROPRANOLOL fu
![Page 36: Effects of Liver Disease on Pharmacokinetics · Effects of Liver Disease on Pharmacokinetics Juan J.L. Lertora, M.D., Ph.D. Director Clinical Pharmacology Program November 3, 2011](https://reader031.fdocuments.us/reader031/viewer/2022022710/5bf208bd09d3f2fb7d8c9242/html5/thumbnails/36.jpg)
36
CIRRHOSIS AFFECTS RENAL FUNCTION:
THE HEPATORENAL SYNDROME
-Risk in Patients with Cirrhosis, Ascitis, and GFR > 50
mL/min:
- 18% within 1 year
- 39% within 5 years
- Predictors of Risk:
- Small liver
- Low serum albumin
- High plasma renin
- Cockcroft and Gault Equation may overestimate
renal function
![Page 37: Effects of Liver Disease on Pharmacokinetics · Effects of Liver Disease on Pharmacokinetics Juan J.L. Lertora, M.D., Ph.D. Director Clinical Pharmacology Program November 3, 2011](https://reader031.fdocuments.us/reader031/viewer/2022022710/5bf208bd09d3f2fb7d8c9242/html5/thumbnails/37.jpg)
37
CIRRHOSIS AFFECTS RENAL FUNCTION:
THE HEPATORENAL SYNDROME
- The Syndrome has a FUNCTIONAL
rather than an Anatomical Basis.
![Page 38: Effects of Liver Disease on Pharmacokinetics · Effects of Liver Disease on Pharmacokinetics Juan J.L. Lertora, M.D., Ph.D. Director Clinical Pharmacology Program November 3, 2011](https://reader031.fdocuments.us/reader031/viewer/2022022710/5bf208bd09d3f2fb7d8c9242/html5/thumbnails/38.jpg)
38
HEPATORENAL SYNDROME
ANTEMORTEM ARTERIOGRAM
There is no renal perfusion.
![Page 39: Effects of Liver Disease on Pharmacokinetics · Effects of Liver Disease on Pharmacokinetics Juan J.L. Lertora, M.D., Ph.D. Director Clinical Pharmacology Program November 3, 2011](https://reader031.fdocuments.us/reader031/viewer/2022022710/5bf208bd09d3f2fb7d8c9242/html5/thumbnails/39.jpg)
39
HEPATORENAL SYNDROME
POSTMORTEM Arteriogram
Renal perfusion appears normal.
![Page 40: Effects of Liver Disease on Pharmacokinetics · Effects of Liver Disease on Pharmacokinetics Juan J.L. Lertora, M.D., Ph.D. Director Clinical Pharmacology Program November 3, 2011](https://reader031.fdocuments.us/reader031/viewer/2022022710/5bf208bd09d3f2fb7d8c9242/html5/thumbnails/40.jpg)
40
CIRRHOSIS AFFECTS RENAL FUNCTION: THE HEPATORENAL SYNDROME
- Therapy with some drugs may precipitate
Hepatorenal Syndrome
ACE Inhibitors
NSAIDs
Furosemide (High Total Doses)
![Page 41: Effects of Liver Disease on Pharmacokinetics · Effects of Liver Disease on Pharmacokinetics Juan J.L. Lertora, M.D., Ph.D. Director Clinical Pharmacology Program November 3, 2011](https://reader031.fdocuments.us/reader031/viewer/2022022710/5bf208bd09d3f2fb7d8c9242/html5/thumbnails/41.jpg)
41
CIRROSIS MAY AFFECT
DRUG DISTRIBUTION
- Increased Free Concentration of
NON-RESTRICTIVELY Eliminated Drugs
(e.g. PROPRANOLOL)
- Increased Permeability of Blood:CNS Barrier
(e.g. CIMETIDINE)
![Page 42: Effects of Liver Disease on Pharmacokinetics · Effects of Liver Disease on Pharmacokinetics Juan J.L. Lertora, M.D., Ph.D. Director Clinical Pharmacology Program November 3, 2011](https://reader031.fdocuments.us/reader031/viewer/2022022710/5bf208bd09d3f2fb7d8c9242/html5/thumbnails/42.jpg)
42
CIRRHOSIS AFFECTS DRUG DISTRIBUTION: INCREASED CNS PENETRATION OF CIMETIDINE*
Chart showing cimetidine CSF/serum ratio from normal to renal + liver disease to liver
disease
* From Schentag JJ, et al. Clin Pharmacol Ther 1981;29:737-43
![Page 43: Effects of Liver Disease on Pharmacokinetics · Effects of Liver Disease on Pharmacokinetics Juan J.L. Lertora, M.D., Ph.D. Director Clinical Pharmacology Program November 3, 2011](https://reader031.fdocuments.us/reader031/viewer/2022022710/5bf208bd09d3f2fb7d8c9242/html5/thumbnails/43.jpg)
43
CIRRHOSIS MAY AFFECT PHARMACODYNAMICS
- Sedative response to BENZODIAZEPINES is exaggerated
- Response to LOOP DIURETICS is reduced
![Page 44: Effects of Liver Disease on Pharmacokinetics · Effects of Liver Disease on Pharmacokinetics Juan J.L. Lertora, M.D., Ph.D. Director Clinical Pharmacology Program November 3, 2011](https://reader031.fdocuments.us/reader031/viewer/2022022710/5bf208bd09d3f2fb7d8c9242/html5/thumbnails/44.jpg)
44
DRUG DOSING IN PATIENTS WITH LIVER DISEASE
The Central Problem:
There is no laboratory test of liver function that is as useful for guiding drug dose
adjustment in patients with liver disease as is the estimation of creatinine clearance in
patients with impaired renal function.
![Page 45: Effects of Liver Disease on Pharmacokinetics · Effects of Liver Disease on Pharmacokinetics Juan J.L. Lertora, M.D., Ph.D. Director Clinical Pharmacology Program November 3, 2011](https://reader031.fdocuments.us/reader031/viewer/2022022710/5bf208bd09d3f2fb7d8c9242/html5/thumbnails/45.jpg)
45
PUGH-CHILD CLASSIFICATION
OF LIVER DISEASE SEVERITY
Chart showing assessment parameters with assigned score and classification of clinical
severity of mild, moderate and severe.
![Page 46: Effects of Liver Disease on Pharmacokinetics · Effects of Liver Disease on Pharmacokinetics Juan J.L. Lertora, M.D., Ph.D. Director Clinical Pharmacology Program November 3, 2011](https://reader031.fdocuments.us/reader031/viewer/2022022710/5bf208bd09d3f2fb7d8c9242/html5/thumbnails/46.jpg)
46
Drugs CONTRAINDICATED in Patients with Severe Liver Disease
- May precipitate renal failure:
- NSAIDs
- ACE Inhibitors
- Predispose to bleeding:
- β-LACTAMS with N-Methylthiotetrazole Side Chain
(e.g. CEFOTETAN)
![Page 47: Effects of Liver Disease on Pharmacokinetics · Effects of Liver Disease on Pharmacokinetics Juan J.L. Lertora, M.D., Ph.D. Director Clinical Pharmacology Program November 3, 2011](https://reader031.fdocuments.us/reader031/viewer/2022022710/5bf208bd09d3f2fb7d8c9242/html5/thumbnails/47.jpg)
47
Drug Requiring ≥ 50% Dose Reduction in Patients
with MODERATE CIRRHOSIS
CHANGE IN CIRRHOSIS
F CLE
ANALGESIC DRUGS
Morphine ↑ 213% ↓ 59%
Meperidine ↑ 94% ↓ 46%
Pentazocine ↑ 318% ↓ 50%
![Page 48: Effects of Liver Disease on Pharmacokinetics · Effects of Liver Disease on Pharmacokinetics Juan J.L. Lertora, M.D., Ph.D. Director Clinical Pharmacology Program November 3, 2011](https://reader031.fdocuments.us/reader031/viewer/2022022710/5bf208bd09d3f2fb7d8c9242/html5/thumbnails/48.jpg)
48
Drugs Requiring ≥ 50% Dose Reduction in Patients
with MODERATE CIRRHOSIS
CHANGE IN CIRRHOSIS
F CLE
CARDIOVASC. DRUGS
Propafenone ↑ 257% ↓ 24%
Verapamil ↑ 136% ↓ 51%
Nifedipine ↑ 78% ↓ 60%
Losartan ↑ 100% ↓ 50%
![Page 49: Effects of Liver Disease on Pharmacokinetics · Effects of Liver Disease on Pharmacokinetics Juan J.L. Lertora, M.D., Ph.D. Director Clinical Pharmacology Program November 3, 2011](https://reader031.fdocuments.us/reader031/viewer/2022022710/5bf208bd09d3f2fb7d8c9242/html5/thumbnails/49.jpg)
49
Drugs Requiring ≥ 50% Dose Reduction in Patients
with MODERATE CIRRHOSIS
CHANGE IN CIRRHOSIS
F CLE
OTHER DRUGS
Omeprazole ↑ 75% ↓ 89%
Tacrolimus ↑ 33% ↓ 72%
![Page 50: Effects of Liver Disease on Pharmacokinetics · Effects of Liver Disease on Pharmacokinetics Juan J.L. Lertora, M.D., Ph.D. Director Clinical Pharmacology Program November 3, 2011](https://reader031.fdocuments.us/reader031/viewer/2022022710/5bf208bd09d3f2fb7d8c9242/html5/thumbnails/50.jpg)
50
RECOMMENDED EVALUATION OF
PHARMACOKINETICS IN LIVER DISEASE
PATIENTS*
REDUCED Study Design:
- Study Control Patients and Patients with Child-Pugh
- Moderate Impairment
- - Findings in Moderate Category Applied to Mild
- Category; Dosing Prohibited in Severe Category
FULL Study Design:
- Study Control Patients and Patients in All Child-Pugh
Categories
- Population PK Approach
* FDA Clinical Pharmacology Guidance, May 2003